Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195676 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,469
- Enrollment target
NCT00195676: Completed Phase 3 study, sponsored by Abbott.
NCT00195676 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 1,469 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00195676, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,469 participants
- Enrollment target
Study Summary
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.
Primary Outcome
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
Interventions
- DRUG adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,469 participants |
| Start Date | 2004-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
What the finished NCT00195676 record still lists
NCT00195676 is an interventional study that assigns participants to a tested intervention. Its 1,469 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% higher).
The record links to 0 conditions, and to 1 intervention - of which adalimumab is the first listed.
NCT00195676 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00195676 about?
NCT00195676 is a clinical study titled "Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis". The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were ...
What is the current status of trial NCT00195676?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,469 participants. The study started on 2004-05. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00195676?
The interventions under investigation include: adalimumab (DRUG).
Who is sponsoring clinical trial NCT00195676?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00195676's enrollment target sits among peer trials
1,469 163rd of 2000 higher than 1,838 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT05869552 · 1,485 participants · NA
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia